A state law passed during the 2021 RI General Assembly session which addressed out-of-pocket costs for insulin drugs. Effective 1 de enero de 2022, in accordance with RIGL § 27-20.8-3, copayments for insulin prescription drugs will not exceed $40 for each thirty-day supply and are not subject to a deductible.

Prescription drug claims for insulin submitted by participating pharmacies will be processed with a patient out-of-pocket charge for the lower of $40, the applicable prescription copayment, or pharmacy charge per month supply. All formulary-covered insulin products will be eligible for this benefit. Application of the benefit will not be limited or require satisfaction of any benefit-defined deductible.

BASAGLAR     INJ 100UNIT

HUMULIN R    INJ U-500    

INSULIN ASPA INJ 100/ML

INSULIN ASPA INJ 70/30   

LANTUS       INJ 100/ML     

LEVEMIR      INJ     

NOVOLIN      INJ 70/30       

NOVOLIN N    INJ U-100    

NOVOLIN R    INJ U-100    

NOVOLOG      INJ 100/ML

NOVOLOG MIX - INJ 70/30

TOUJEO MAX INJ300IU/ML